IL2 and acute myeloid leukemia: As a postapproval requirement by the EMA, the Re:Mission single-arm phase IV trial, performed in four European countries, assessed the immunomodulatory effects of HDC/IL-2.16,17,55, , , , –60 In this trial, AML patients (n = 84, age 18–79, all in CR1) received ten 3-week cycles of HDC/IL-2 (the same schedule and dosing as in the phase III trial) with peripheral blood mononuclear cells collected before and after treatment cycles 1 and 3.